is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and Results-The circulating concentration of GDF-15 was measured at baseline (nϭ1734) and at 12 months (nϭ1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (Ͼ1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; PϽ0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; PϽ0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; Pϭ0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups (Pϭ0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. Conclusions-GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT. (Circulation. 2010;122:1387-1395.)
T here is a growing interest in using circulating biomarkers to obtain pathophysiological insight into and, possibly, to improve the management of patients with heart failure (HF). 1, 2 Considering that HF is a systemic disease, biomarkers reflecting cardiac and systemic abnormalities in HF may add incremental information to cardiac-specific markers such as B-type natriuretic peptide (BNP).
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Growth-differentiation factor-15 (GDF-15) is a distant member of the transforming growth factor-␤ cytokine superfamily. 3 Although GDF-15 is weakly expressed in most tissues under physiological conditions, its expression may increase significantly in response to inflammation and tissue injury. 4 -7 Ischemia, mechanical stretch, neurohormones such as angiotensin II, and proinflammatory cytokines stimulate the expression of GDF-15 in cultured cardiac myocytes. 7, 8 Increased cardiac expression of GDF-15 has been observed in mouse models of myocardial infarction, pressure overload, and HF, 7, 9 indicating that GDF-15 shares some of its upstream regulatory stimuli with BNP. 10 In contrast to BNP, which is produced almost exclusively in the heart, 11 is not a cardiac-specific factor. Other cardiovascular cell types, including endothelial cells, vascular smooth muscle cells, and adipocytes, have been shown to produce GDF-15 under stressful conditions. [12] [13] [14] Moreover, GDF-15 has been detected in atherosclerotic plaque macrophages, where it may be induced by oxidized low-density lipoprotein and proinflammatory cytokines. 3, 6 Accumulating evidence indicates that circulating levels of GDF-15 are associated with prognosis in patients with cardiovascular disease. The data are strongest in stable and unstable coronary artery disease, in which GDF-15 has been found to be associated with the risk of death and myocardial infarction independent of clinical variables, renal function, and other biomarkers, including C-reactive protein (CRP), N-terminal pro-BNP, and cardiac troponins. [15] [16] [17] [18] Comparatively little is known about the potential role of GDF-15 as a biomarker in HF. In an initial study in 455 HF patients, baseline levels of GDF-15 were associated with all-cause mortality during 1 year of follow up. GDF-15 added prognostic information to New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), and N-terminal pro-BNP in that study, suggesting that GDF-15 may provide insight into a distinct pathophysiological process. 19 A recent study in 158 patients with advanced HF receiving resynchronization therapy confirmed that GDF-15 can add prognostic information to N-terminal pro-BNP. 20 In the present investigation, we used the large and variable-rich Valsartan Heart Failure Trial (Val-HeFT) database to identify baseline variables associated with the levels of GDF-15, to evaluate whether baseline measurements of GDF-15 provide independent prognostic information about mortality and a combined mortality and morbidity end point, and to examine changes in GDF-15 over time and their relationship to subsequent morbidity and mortality.
Methods

Study Design and Patient Selection
Val-HeFT was a randomized, placebo-controlled, double-blind, multicenter trial that enrolled 5010 men and women with symptomatic HF to evaluate the efficacy of the angiotensin receptor blocker valsartan. 21 The study had 2 primary end points: mortality and the first morbid event, defined as death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilator drugs for Ն4 hours without hospitalization.
GDF-15 and Other Measurements
Plasma was sampled and stored at Ϫ70°C at baseline and at 4, 12, and 18 months after randomization. At the same time points, hemoglobin, serum albumin, electrolytes, creatinine, uric acid, highsensitivity CRP (hs-CRP), high-sensitivity troponin T (hs-TnT), neurohormones (BNP, norepinephrine, aldosterone), LVEF, and left ventricular internal diastolic dimension corrected for body surface area were also measured. Plasma renin activity was measured only at baseline. For the present study, 1734 baseline samples and 1517 samples at 12 months were available for measurement of GDF-15 by a recently developed immunoradiometric assay. 22 On average, each aliquot had been thawed and refrozen twice. Four cycles of freezing and thawing of blood samples and storage at room temperature for up to 48 hours have previously been shown not to induce a discernible loss of GDF-15 immunoreactivity. 22 The assay has a limit of detection of 20 ng/L, an intra-assay and interassay imprecision of Յ12.2%, and a linear range from 200 to 50 000 ng/L. 22 Estimated glomerular filtration rate (eGFR) was calculated with the Modification of Diet in Renal Disease (MRDS) equation.
Data Analysis
The logarithm (log 10 ) of the GDF-15 levels was related to other baseline characteristics through the use of single and multiple variable linear regression. Kaplan-Meier survivor curves estimated within each quartile of baseline GDF-15 were examined to help determine the relationship between baseline GDF-15 and the cumulative event-free survival. To determine whether GDF-15 was independently associated with time to end-point events, GDF-15 was added to a comprehensive Cox regression model of previously recognized clinical prognostic variables, including age, gender, presence of ischemic heart disease, NHYA class, orthopnea, diabetes mellitus, body mass index, systolic blood pressure, heart rate, atrial fibrillation, LVEF, hemoglobin, serum sodium, albumin, uric acid, eGFR, use of an angiotensin-converting enzyme inhibitor, ␤-blocker, diuretic, digoxin, spironolactone, and the Val-HeFT treatment allocation (model 1). In a second step, BNP, hs-CRP, and hs-TnT, transformed with natural logarithms, were added to model 1 (model 2).
To examine the discrimination of end-point events, we examined the area under the receiver-operating characteristic (ROC) curve (plot of sensitivity versus 1Ϫspecificity for all possible cutoff values for classifying predictions) for GDF-15 and the change in the ROC area when GDF-15 was added to a logistic regression of the groups that either did or did not experience the end-point event within 1 year that included either all model 1 or model 2 variables. Areas under the ROC curves were compared using the method of DeLong et al 23 for paired data. Similar methods were used to compare ROC curves for some of the individual biomarkers measured at baseline. The integrated discrimination improvement was also estimated for the regression models as a measure of the average change in sensitivity minus the average change in 1Ϫspecificity with the addition of GDF-15 and tested for statistical significance with the simple asymptotic methods of Pencina et al. 24 Changes in GDF-15 levels from baseline to 12 months were analyzed within the groups randomly assigned to placebo or valsartan with the signed-ranks test. The rank-sum test was used to compare changes in GDF-15 levels between treatment groups. The Spearman rank correlation coefficients were calculated to examine relationships between changes in GDF-15 levels and changes in other variables over 12 months within the placebo and valsartan treatment groups. Multiple variable linear regression analysis was used to identify baseline and change variables that were independently associated with a change in GDF-15 level at 12 months. The relationship between changes in GDF-15 over 12 months and subsequent end-point events was examined with Cox regression models that included baseline GDF-15 and several other variables in models 1 through 4. Model 1 contains all the baseline clinical variables listed above. Model 2 is model 1 plus baseline ln BNP, ln hs-CRP, and ln hs-TnT. Model 3 is model 2 plus change from baseline to 12 months in the nonfixed clinical variables. Model 4 is model 3 plus change from baseline to 12 months in BNP, hs-CRP, and hs-TnT. SPSS (version 12.0, SPSS Inc, Chicago, Ill) and Stata (version 10.0, Stata Corp, College Station, Tex) were used to analyze the data. A 2-tailed value of PՅ0.05 was considered statistically significant. No adjustments for making multiple statistical comparisons were made because these analyses are considered exploratory.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Baseline Correlates of GDF-15
The median plasma level of GDF-15 at baseline was 2040 ng/L (interquartile range, 1426 to 3027 ng/L; range, 259 to 25 637 ng/L; nϭ1734); 85% of the study population presented with a GDF-15 level Ͼ1200 ng/L, the previously defined upper reference limit in apparently healthy elderly individuals. 22 Compared with Val-HeFT patients who did not have GDF-15 measured (nϭ3276), patients with GDF-15 measurements, included in this analysis, had worse HF with higher NYHA class, worse quality of life, greater signs of fluid retention, lower blood pressure, lower hemoglobin, higher neurohormones, higher hs-CRP, and higher hs-TnT (data in Table I in the online-only Data Supplement). Therefore, the results in our subgroup who had GDF-15 levels measured might be different from what would have been found in the entire Val-HeFT sample.
Baseline characteristics of the patients in relation to baseline GDF-15 are shown in Table 1 . Although GDF-15 was significantly associated with a large number of variables, based on the R 2 , the strongest relation of GDF-15 was with eGFR, hs-TnT, age, BNP, and uric acid. Table 2 shows the baseline variables that were independently related to GDF-15. Combined, these variables explained a considerable proportion of the variation in GDF-15 levels (R 2 ϭ0.63).
Association Between Baseline GDF-15 and End-Point Events
During a median follow-up of 23 months (interquartile range, 17 to 30 months), 367 patients (21%) died and 584 patients (34%) had a first morbid event. Patients who died had a higher baseline GDF-15 (median, 2804 ng/L; interquartile range, 1871 to 4382 ng/L) compared with those who survived (median, 1884 ng/L; interquartile range, 1356 to 2703 ng/L), as shown in the box plot ( Figure 1 ).
The unadjusted Kaplan-Meier curves ( Figure 2 ) indicated that the risk of adverse outcomes increased with the highest levels of GDF-15. In Cox regression analyses in which the dependent variable is the natural logarithm of the cumulative hazard ratio (HR), the relationship with GDF-15 appeared to be linear, judging by plots of GDF-15 levels versus Martingale residuals and linear spline analyses (not shown). A 100-ng/L higher baseline GDF-15, as a continuous variable, was associated with an estimated 1.7% greater risk of mortality (HR, 1.017; 95% confidence interval [CI], 1.014 to 1.019; PϽ0.001) and 2.0% greater risk of first morbid event (HR, 1.020; 95% CI, 1.017 to 1.023; PϽ0.001) in an unadjusted Cox model. When GDF-15 was added to the comprehensive clinical multiple-variable Cox regression model (model 1), GDF-15 remained independently associated with an increased risk of mortality (adjusted HR, 1.010; 95% CI, 1.006 to 1.015; PϽ0.001) and first morbid event (adjusted HR, 1.011; 95% CI, 1.006 to 1.015; PϽ0.001; Table 3 ). Furthermore, adding the GDF-15 level to a logistic regression analysis of deaths within 1 year that contained model 1 variables significantly increased the area under the ROC curve of the model derived from individual predicted probabilities from 0.68 (95% CI, 0.62 to 0.73) to 0.71 (95% CI, 0.66 to 0.76; Pϭ0.03) and from 0.70 (95% CI, 0.66 to 0.73) to 0.72 (95% CI, 0.68 to 0.75; Pϭ0.01) for the first morbid events. The integrated discrimination improvements for mortality (Ϫ0.005; 95% CI, Ϫ0.017 to 0.006; Pϭ0.25) and morbidity (0.002; 95% CI, Ϫ0.008 to 0.012; Pϭ0.67) were not significantly different from zero.
When BNP, hs-CRP, and hs-TnT were added to model 1 to create model 2, GDF-15 baseline levels still remained independently associated with mortality (adjusted HR, 1.007; 95% CI, 1.001 to 1.014; Pϭ0.02) but not with the first morbid event (adjusted HR, 1.003; 95% CI, 0.997 to 1.008; Pϭ0.34). Adding the GDF-15 level to a logistic regression analysis of deaths within 1 year that contained model 2 variables significantly increased the area under the ROC curve of the model from 0.73 (95% CI, 0.67 to 0.78) to 0.76 (95% CI, 0.71 to 0.81; Pϭ0.02) and from 0.73 (95% CI, 0.69 to 0.77) to 0.76 (95% CI, 0.72 to 0.79; Pϭ0.005) for the first morbid events. The integrated discrimination improvements for mortality (0.012; 95% CI, Ϫ0.0004 to 0.024; Pϭ0.06) and morbidity (0.011; 95% CI, 0.001 to 0.02; Pϭ0.04) tended to indicate improvement with the addition of GDF-15 to model 2.
A number of subgroup analyses were conducted to investigate whether the risk associated with high GDF-15 levels depended on other risk factors (age, gender, NYHA class, cause of heart failure, blood pressure, heart rate, renal dysfunction, or LVEF). The relationship between GDF-15 and mortality did not depend on other risk factors except cause of heart failure (ischemic/nonischemic) with an interaction value of Pϭ0.048. In the subgroups with HF of an ischemic cause of heart failure, the HR was lower (HR, 1.013; 95% CI, 1.010 to 1.017; nϭ967) than in the subgroup with nonischemic cardiomyopathy (HR, 1.024; 95% CI, 1.019 to 1.030; nϭ767), although GDF-15 was significantly (PϽ0.001) related to mortality in both subgroups.
To further explore whether the prognostic information provided by GDF-15 was additive to the information provided by the cardiac-specific markers BNP and hs-TnT, the median baseline values of GDF-15 (2040 ng/L), BNP (97 pg/mL), and hs-TnT (14.9 ng/mL) were used to split the patient population into groups of comparable sizes. As shown in Figure 3 , the combination of GDF-15 and BNP or hs-TnT identified subgroups with significantly different mortality (PϽ0.001). Similar results were obtained relative to the risk of a first morbid event (results not shown).
Comparison of GDF-15 to BNP, hs-TnT, and hs-CRP for Discrimination of First-Year Outcome
During the first year of follow-up, 156 patients (9%) died and 314 (18%) experienced a first morbid event. Only 1 patient who did not have an end-point event had less than a full year of follow-up and thus was excluded from this particular analysis. When the 4 biomarkers were analyzed as continuous variables, the area under the ROC curve for mortality within a year for GDF-15 (0.67; 95% CI, 0.62 to 0.72) was no different than that for BNP (0.68; 95% CI, 0.63 to 0.73) or hs-TnT (0.70; 95% CI, 0.65 to 0.74) and was significantly greater than that for hs-CRP (0.57; 95% CI, 0.52 to 0.62; PϽ0.001). The area under the ROC curve for the first morbid event for GDF-15 (0.67; 95% CI, 0.63 to 0.70) was also similar to that for BNP (0.66; 95% CI, 0.63 to 0.70) but was smaller than that for hs-TnT (0.71; 95% CI, 0.68 to 0.74; PϽ0.004) and greater than that for hs-CRP (0.56; 95% CI, 0.52 to 0.60; PϽ0.001).
Changes in GDF-15 Levels Over Time
Levels of GDF-15 were similar at baseline in the groups randomly assigned to placebo (median, 1942 ng/L; interquar- Thirteen extreme values that greatly exceed 10 000 (4 in the deceased group and 9 in the survivor group) were excluded to make the scale more presentable. ACE indicates angiotensin-converting enzyme. GDF-15 was analyzed as a log 10 -transformed variable. Results are sorted by the standardized coefficients. Only significant independent variables are shown. All significant variables listed in Table 1 were included in this regression analysis except heart rate, which was excluded given that use of a ␤-blocker was included. There were 1283 subjects without any missing values. tile range, 1398 to 2856 ng/L) or valsartan (median, 2043 ng/L; interquartile range, 1419 to 2961 ng/L). Among survivors at 12 months, the GDF-15 levels were significantly higher than baseline levels in both the placebo (median change, 145 ng/L; interquartile range, Ϫ151 to 594 ng/L; range, Ϫ7862 to 30 149 ng/L; PϽ0.001; nϭ668) and valsartan (median change, 173 ng/L; interquartile range, Ϫ157 to 603 ng/L; range, Ϫ5000 to 11 856 ng/L; PϽ0.001; nϭ656) treatment groups. The increases in GDF-15 levels at 12 months were not significantly different between groups (Pϭ0.94). BNP levels, in contrast, showed a slight increase from baseline to 12 months in the placebo group (median change, 3 pg/mL; interquartile range, Ϫ33 to 53 pg/mL; Pϭ0.014; nϭ663) and a significant decrease in the valsartan group (median change, Ϫ10 pg/mL; interquartile range, Ϫ66 to 18 pg/mL; PϽ0.001; nϭ650).
In both the placebo and valsartan groups, the 12-month changes in GDF-15 levels were most significantly (all at least PϽ0.01) related to the changes in hs-TnT (ϭ0.38 and 0.36, respectively), uric acid (ϭ0.30 and 0.27), eGFR (ϭϪ0.24 and Ϫ0.39), hs-CRP (ϭ0.23 and 0.19), BNP (ϭ0.23 and 0.18), norepinephrine (ϭ0.22 and 0.12), systolic blood pressure (ϭϪ0.18 and Ϫ0.16), and hemoglobin (ϭϪ0. 13 and Ϫ0.22) . In a multiple variable linear regression analysis that included patients from both treatment groups and all the clinical and biochemical baseline and change variables, changes in BNP, eGFR, hs-TnT, uric acid, hemoglobin, and systolic blood pressure, as well as baseline eGFR, GDF-15, BNP, LVEF, and hs-CRP, were independently associated with change in GDF-15 at 12 months (Table 4 ). 
Change in GDF-15 Over 12 Months and Subsequent Events
Because changes in GDF-15 over 12-months were similar in the placebo and valsartan groups, the prognostic implications of changes in GDF-15 levels over time were assessed in both groups combined. There were 1324 patients who survived 1 year and had GDF-15 values at baseline and 1 year. After the first year of follow-up, 167 patients (14.4%) died. There were 1221 patients who did not have the first morbid event in the first year. Among these, 231 (18.9%) had a subsequent first morbid event. Table 5 shows the results of Cox regression analyses for mortality and first morbid event in relation to 12-month changes in GDF-15 as a continuous variable adjusted for baseline GDF-15 levels. Model 1 contains all the baseline clinical variables listed in the Data Analysis section; model 2 is model 1 plus baseline BNP, hs-CRP, and hs-TnT; model 3 is model 2 plus change from baseline to 12 months in the nonfixed clinical variables; and model 4 is model 3 plus change from baseline to 12 months in BNP, hs-CRP, and hs-TnT. As can be seen, changes in GDF-15 at 12 months were significantly associated with mortality and the first morbid event in all 4 models.
Discussion
The present analyses of data from the Val-HeFT trial indicate that GDF-15 levels are associated with several pathological processes that have been linked to the severity and progression of HF, including neurohormonal activation, inflammation, myocyte death, and renal dysfunction, and show that circulating levels of GDF-15 are associated with adverse outcomes independently of established clinical and biochemical risk markers. Furthermore, in this HF population in which 35% of the patients were treated with ␤-blockers and very few were receiving spironolactone, increases in GDF-15 levels were observed over time that were independently associated with prognosis.
Baseline Correlates of GDF-15
The majority of our patient population had supranormal levels of GDF-15, and the levels of GDF-15 were related to clinical, echocardiographic, and biochemical markers of more severe HF. Renal dysfunction, age, diabetes mellitus, and the circulating concentrations of hs-TnT, hs-CRP, and norepinephrine were among the main factors that were independently associated with elevated levels of GDF-15 at baseline. Neurohormones and proinflammatory cytokines have been shown to enhance the expression of GDF-15 in cardiac myocytes and other cell types. 3,6 -8 GDF-15 was independently associated with norepinephrine and hs-CRP in the present study, supporting a link between GDF-15 neurohormonal activation and inflammation. Elevated circulating levels of hs-TnT are thought to reflect ongoing cardiac myocyte cell death in HF, 25 which may be related to myocardial ischemia, myocyte stretch, and inflammation. 26 Notably, the same mechanisms induce the expression of GDF-15 in cardiac myocytes and in the murine heart, [7] [8] [9] suggesting that GDF-15 may be an indicator of these stressful conditions. Results are sorted by standardized coefficient. Only significant independent variables are shown. All significant baseline variables listed in Table 1 and the 12-month changes in nonfixed baseline variables were included in this regression analysis except heart rate, which was excluded given that use of a ␤-blocker was included. Only statistically significant independent variables are shown. There were 917 subjects with values of 12-month change in GDF-15 without any missing covariates. The independent associations of GDF-15 with age, diabetes mellitus, and renal dysfunction found in this study have also been observed in patients with coronary artery disease and no HF. 15, 16, 18 Higher levels of GDF-15 with renal dysfunction suggest that GDF-15 is cleared from the circulation by the kidneys and/or that GDF-15 synthesis is increased in renal disease, as has been described in animal models. 27, 28 
Table 5. Unadjusted and Adjusted Cox Regression Analyses of the Association Between Changes in GDF-15 at 12 Months as a Continuous Variable and Subsequent Risks of Mortality and First Morbid Event
GDF-15 and Prognosis in HF
The baseline levels of GDF-15 were associated with the risks of mortality and first morbid event. Considering the independent association of GDF-15 with adverse outcome in patients with coronary artery disease, [15] [16] [17] [18] it is interesting to note that GDF-15 was related to outcome in patients with HF that was or was not attributed to ischemic heart disease. In fact, the association appeared to be stronger for patients with nonischemic cardiomyopathy. Differences in the relation between GDF-15 and mortality risk between patients with ischemic and nonischemic HF, however, were not observed in a previous smaller study, 19 which raises the possibility of a spurious finding in this posthoc subgroup analysis.
In the present analysis, GDF-15 levels remained independently associated with the risk of death and first morbid event when added to a comprehensive clinical risk prediction model that included many other prognostic variables that were correlated with GDF-15 (model 1). Even after further adjustment for BNP, hs-CRP, and hs-TnT (model 2), GDF-15 remained an independent predictor of mortality, indicating that GDF-15 carries unique prognostic information. Along this line, combining GDF-15 with BNP or hs-TnT allowed identification of patient subgroups with substantially differing risks of adverse outcome events.
GDF-15 improved the discrimination of outcome groups as assessed by ROC curve analyses of death and first morbid event within 1 year for models 1 and 2 and when discrimination was assessed by the integrated discrimination improvement for first morbid event in model 2. The multiple variable risk prediction models 1 and 2 include information on clinical status, therapy, and laboratory parameters that have been shown to provide prognostic information in HF. 29 -33 It is remarkable that GDF-15 added further discriminatory information to this comprehensive set of prognostic variables that included other HF biomarkers. However, the magnitude of net improvement in sensitivity and specificity when GDF-15 was added to these extensive models was not substantial.
Repeat Measurement of GDF-15 and Outcome in HF
The circulating levels of GDF-15 increased over the course of 12 months in patients randomized to the placebo arm. Treatment with valsartan did not prevent this increase and may have contributed to it because eGFR was reduced by valsartan in this cohort. 34 Consistent with the observations at baseline, increases in GDF-15 over the course of 12 months were independently associated with worsening renal function and increasing levels of biomarkers reflecting cardiac strain, injury (BNP and hs-TnT), and inflammation (uric acid). It should be pointed out, however, that such analyses might provide only limited insight into the pathobiology of GDF-15 (the same caveat applies for the association analyses performed at baseline). In a recent epidemiological study, the circulating levels of GDF-15 were associated with left ventricular mass, left ventricular systolic dysfunction, endothelial dysfunction, and atherosclerotic plaque burden after adjustment for traditional cardiovascular risk factors. 35 Although similar analyses are not available in HF patients, the hypothesis that GDF-15 carries information on cardiac and vascular pathologies that is related to future adverse events should be pursued further.
Changes in GDF-15 over time were independently associated with subsequent risks of mortality and first morbid event even after adjustment for all baseline variables and their concurrent changes in several comprehensive models. It is notable that the intraindividual biological variation of GDF-15 in patients with clinically stable chronic HF is lower compared with the intraindividual biological variation of the natriuretic peptides, 36, 37 which may facilitate interpretation of temporal changes in GDF-15 in HF. Previous studies using echocardiography or repeat measurements of BNP found no evidence for a progressive worsening of cardiac function in patients from the Val-HeFT trial over the course of 12 months; in fact, slight improvements in LVEF and decreases in left ventricular internal diastolic dimension corrected for body surface area and BNP have been reported. 31, 38 In agreement with this, we observed a significant decrease in BNP levels from baseline to 12 months in the valsartan group in the present subpopulation from the Val-HeFT trial. Taken together, these data indicate that changes in GDF-15 over time may reflect pathophysiological processes that are related to the progression and prognosis of HF and that are not completely addressed by the therapies prescribed to the patients in Val-HeFT.
Conclusions
GDF-15 and the changes thereof are associated with prognosis independently of many other clinical characteristics and biomarkers of the severity of the disease. How the prognostic information provided by GDF-15 could be used clinically, alone or in combination with other biomarkers, for patient monitoring and formulating treatment decisions remains to be investigated. Continued research should focus on an improved understanding of the pathophysiology of GDF-15 in HF that could lead to new treatment targets in HF. 
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